Technical analysis of NeuroSense Therapeutics Ltd. (NRSN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).
Price Performance
| 1 month | -15.05% |
| 3 months | -59.66% |
| Year-to-date | -57.80% |
| 1 year | -72.50% |
| 3 years | -60.55% |
52-Week Range
| 52-week High | $26.60 |
| 52-week Low | $5.00 |
| Avg Volume (90d) | 15K |
Technical Indicators
| SMA 50 | $10.04 |
| SMA 200 | $15.21 |
| Beta | 1.68 |
| 30-day Volatility (annualised) | 130.7% |
| Price vs SMA 50 | -35.3% |
| Price vs SMA 200 | -57.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $22.40 | |
| 2025-11 | $23.80 | +6.3% |
| 2025-12 | $15.38 | -35.4% |
| 2026-01 | $18.40 | +19.6% |
| 2026-02 | $18.18 | -1.2% |
| 2026-03 | $15.10 | -16.9% |
| 2026-04 | $16.42 | +8.7% |
| 2026-05 | $16.43 | +0.1% |
| 2026-06 | $14.40 | -12.4% |
| 2026-07 | $9.30 | -35.4% |
| 2026-08 | $8.53 | -8.3% |
| 2026-09 | $6.49 | -23.9% |
Price
| Price | $6.49 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | -5.76 |
| EV / EBITDA | -1.12 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -0.11 |
| Current Ratio | 0.31 |